AdAPT-001 Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment December 10, 2024
FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma November 19, 2024
FDA Clears IND Application for Ph 1/2 ADCElerate-01 Trial of ADCE-D01 Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS) October 15, 2024
Elraglusib Demonstrated Anti-Tumor Activity with Two Ongoing Durable CRs and ~62% DCR in First 8 Patients with R/R Ewing and Ewing-related Sarcomas September 17, 2024
FDA grants Accelerated Approval to TECELRA® (afamitresgene autoleucel) for advanced MAGE-A4+synovial sarcoma in chemo-treated adults August 7, 2024
First Patient Dosed in Global Randomized Ph 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma July 17, 2024
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated April 16, 2024
FDA accepts BLA for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review February 26, 2024
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash February 26, 2024
European Commission approves Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types January 23, 2024
First Patient Dosed in Ph 1a Trial of QN-302 in Advanced or Metastatic Solid Tumors December 11, 2023
Double-Digit ORR announced in Each Cohort from the Ongoing ENVASARC Ph 2 Pivotal Trial December 19, 2022
INT230-6 +/- Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising OS Results in Adult Subjects with Metastatic Sarcomas November 23, 2022
Durable Responses of Botensilimab/Balstilimab Combination in Nine Different Treatment-Resistant Cancers announced November 23, 2022
New Patient Enrollment in Ph 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas paused after patient death October 26, 2022
